Crinetics Pharmaceuticals CRNX Cash Flow Statement (2017-2026)

NASDAQ CRNX
$84.95 +0.00 (+0.00%)
At close: Sep 2, 2026 · 4:00 PM EDT
Reported Financials

Crinetics Pharmaceuticals Quarterly Cash Flow Statement

Periods 37 quarters
Latest Jun 2026

Crinetics Pharmaceuticals reported cash from operations of -$94.19M and free cash flow of -$94.71M for the quarter ended Jun 2026, down 9.7% year over year. This cash flow statement covers 37 quarters of results from Jun 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
27.85M-184.49M33.62M42.38M41.92M44.99M45.99M50.98M56.46M-362.77M66.46M74.06M-76.83M-80.59M96.77M115.64M-130.09M-122.64M-127.71M-120.43M
Share-based Compensation
4.55M5.16M7.98M8.52M8.90M7.95M11.54M12.42M12.46M11.62M14.46M18.94M18.15M18.84M20.48M26.12M22.70M21.72M29.68M24.88M
Deferred Taxes
Cash from Operations
-25.67M-22.90M-13.54M-27.98M-38.48M-35.21M-40.72M-45.73M-41.34M-40.81M-52.86M-47.64M-62.82M-66.87M-88.45M-85.85M-110.72M-92.90M-124.70M-94.19M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
-0.07M-0.19M-0.32M-0.20M0.13M0.35M0.53M0.91M1.25M3.58M3.85M3.41M3.51M4.16M4.38M4.71M3.60M2.73M2.22M2.02M
Amortization of Deferred Charges
Depreciation & Amortization (CF)Depreciation & Amortization
0.23M0.23M0.24M0.21M0.25M0.28M0.28M0.28M0.27M0.26M0.47M0.75M0.77M0.79M0.93M0.96M1.01M0.99M1.16M1.07M
Change in Working Capital
Change in Receivables
5.09M6.27M
Change in Inventory
0.91M0.36M
Change in Accured Expenses
0.49M3.90M1.53M6.71M-1.33M4.08M-1.34M7.42M4.38M1.90M1.31M5.21M0.69M6.12M-1.36M12.52M6.65M11.18M-12.06M9.29M
Other Working Capital Changes
3.06M0.36M-2.49M-0.74M2.18M0.11M-1.52M11.00M-1.12M-3.85M0.78M-4.67M2.06M7.80M6.92M4.41M7.21M-2.02M7.02M0.46M
Investing Activities
Capital Expenditures
0.14M0.02M0.09M0.61M0.68M0.27M0.03M0.22M3.50M0.94M1.33M0.95M0.53M1.03M1.24M3.20M0.86M0.46M0.82M0.52M
Change in Acquisitions & Divestments
13.96M0.24M11.72M18.90M56.19M70.69M71.44M91.17M87.84M86.68M101.38M139.30M151.15M183.97M306.48M224.03M382.37M271.21M302.89M182.03M
Cash from Investing Activities
-7.03M-101.80M-43.38M-174.27M6.82M36.85M48.76M31.44M-193.30M-87.31M0.31M-53.64M20.60M-542.09M-85.96M37.95M164.81M57.11M-252.36M26.29M
Financing Activities
Other financing activities
0.49M1.85M1.78M1.74M1.09M0.12M0.48M1.12M-10.73M10.36M2.03M10.68M-32.88M4.44M2.88M3.08M-14.58M9.94M8.93M
Debt Issuance and Repayment
Long-Term Debt Issuances
Change in Capital Stock
Net Shares Issued and Repurchased
2,889.00M1.65M4,139.20M2.17M4.82M2.52M3.97M2.15M
Net Equity Issued and Repurchased
14.98M162.01M-0.01M11.31M328.96M29.29M383.21M48.30M543.53M380.51M
Misc.
Cash from Financing Activities
15.46M163.86M1.78M118.99M1.08M0.12M0.48M12.66M337.88M40.22M393.57M7.52M57.33M556.24M4.44M7.05M3.08M26.04M389.88M8.93M
Exchange Rate Effect
-0.01M0.13M
Change in Cash
-17.23M39.16M-55.15M-83.25M-30.58M1.76M8.52M-1.64M103.24M-87.90M341.03M-93.76M15.11M-52.72M-169.98M-40.84M57.17M-9.76M12.81M-58.98M
Free Cash Flow
-25.81M-22.92M-13.63M-28.59M-39.16M-35.48M-40.75M-45.95M-44.84M-41.74M-54.19M-48.60M-63.35M-67.90M-89.69M-89.05M-111.58M-93.36M-125.52M-94.71M
Net Cash Flow
-17.23M39.16M-55.15M-83.25M-30.58M1.76M8.52M-1.64M103.24M-87.90M341.03M-93.76M15.11M-52.72M-169.98M-40.84M57.17M-9.76M12.81M-58.98M